Please login to the form below

Not currently logged in
Email:
Password:

amyloid

This page shows the latest amyloid news and features for those working in and with pharma, biotech and healthcare.

After mixed signals, will Eisai and Biogen press on with Alzheimer’s hopeful?

After mixed signals, will Eisai and Biogen press on with Alzheimer’s hopeful?

However others remain sceptical about the robustness of the data, which is understandable given the track record: the drug relies on the amyloid hypothesis which is looking increasingly shaky after an

Latest news

More from news
Approximately 6 fully matching, plus 107 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon

    The firm focuses on brain health, memory and ageing and its lead product is an oral amyloid aggregation inhibitor that targets Alzheimer's disease. ... Alzheon's founder, president and chief executive officer Martin Tolar said: “JP will provide

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics